| 01/19 | VYNE Therapeutics Completes Phase 1b Data for FMX114 for Atopic Dermatitis | MT |
| 01/19 | VYNE THERAPEUTICS : Announces Phase 1b Data for FMX114 from Phase 1b/2a Trial for the Trea.. | PU |
| 01/19 | VYNE THERAPEUTICS INC. : Other Events, Financial Statements and Exhibits (form 8-K) | AQ |
| 01/19 | VYNE Therapeutics Announces Phase 1b Data for FMX114 from Phase 1b/2a Trial for the Tre.. | AQ |
| 01/19 | VYNE Therapeutics Inc. Announces Phase 1B Data for Fmx114 from Phase 1B/2A Trial for th.. | CI |
| 01/14 | VYNE THERAPEUTICS : Unaudited Pro Forma Condensed Consolidated Financial Information - For.. | PU |
| 01/14 | VYNE THERAPEUTICS INC. Change in Directors or Principal Officers, Financial Statements.. | AQ |
| 01/14 | VYNE Therapeutics Inc. Announces Board Changes | CI |
| 01/14 | Health Care Stocks Drop Premarket Friday | MT |
| 01/13 | Health Care Stocks Losing More Ground as Biotechs Sputter in Late Trade | MT |
| 01/13 | Wall Street Set for Narrow Gains; US Wholesale Prices Rise Less Than Expected in Decemb.. | MT |
| 01/13 | Thinking about buying stock in Adagio Therapeutics, Vyne Therapeutics, PetVivo, BTCS In.. | PR |
| 01/13 | Journey Medical Acquires Vyne Therapeutics' Molecule Stabilizing Technology Franchise | MT |
| 01/13 | VYNE THERAPEUTICS : Divests Topical Minocycline Assets - Form 8-K | PU |
| 01/13 | VYNE THERAPEUTICS INC. : Entry into a Material Definitive Agreement, Completion of Acquisi.. | AQ |
| 01/13 | VYNE Therapeutics Divests Topical Minocycline Assets | AQ |
| 01/13 | Journey Medical Corporation Acquires Two FDA-Approved Topical Minocycline Products and .. | CI |
| 01/05 | VYNE THERAPEUTICS INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form.. | AQ |
| 01/03 | VYNE Therapeutics to Participate at the LifeSci Partners 11th Annual Corporate Access E.. | AQ |
| 2021 | VYNE THERAPEUTICS INC.(NASDAQGS : VYNE) dropped from NASDAQ Biotechnology Index | CI |
| 2021 | Top Premarket Gainers | MT |
| 2021 | VYNE Therapeutics Shares Surge After HC Wainwright Starts Coverage at Buy | MT |
| 2021 | HC Wainwright Assumes VYNE Therapeutics at Buy with $7 Price Target | MT |
| 2021 | Thinking about buying stock in Del Taco Restaurants, Vyne Therapeutics, Lucid Group, AS.. | PR |
| 2021 | VYNE Therapeutics to Present at the Piper Sandler 33rd Annual Virtual Healthcare Confer.. | AQ |
| 2021 | VYNE THERAPEUTICS INC. Management's Discussion and Analysis of Financial Condition and.. | AQ |
| 2021 | VYNE Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months E.. | CI |
| 2021 | VYNE Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Up.. | PU |
| 2021 | VYNE THERAPEUTICS INC. : Results of Operations and Financial Condition, Regulation FD Disc.. | AQ |
| 2021 | VYNE Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Up.. | AQ |
| 2021 | Earnings Flash (VYNE) VYNE THERAPEUTICS Posts Q3 Revenue $4.1M, vs. Street Est of $4.76.. | MT |
| 2021 | Earnings Flash (VYNE) VYNE THERAPEUTICS Reports Q3 Loss $-0.36, vs. Street Est of $-0.3.. | MT |
| 2021 | NORTH AMERICAN MORNING BRIEFING : Stock Futures -3- | DJ |
| 2021 | Lead BET Inhibitor, VYN201, Demonstrates Improvement in Reducing Fibrotic Tissue Mass a.. | PU |
| 2021 | VYNE THERAPEUTICS INC. : Other Events, Financial Statements and Exhibits (form 8-K) | AQ |
| 2021 | Lead BET Inhibitor, VYN201, Demonstrates Improvement in Reducing Fibrotic Tissue Mass a.. | AQ |
| 2021 | VYNE Therapeutics Inc. Announces Preclinical Data from Validated Animal Study Showing I.. | CI |
| 2021 | VYNE Therapeutics to Report Third Quarter 2021 Financial Results on November 10, 2021 | AQ |
| 2021 | Lead BET Inhibitor, VYN201, Significantly Reduces Expression of Several Key Pro-Inflamm.. | PU |
| 2021 | VYNE THERAPEUTICS INC. : Other Events, Financial Statements and Exhibits (form 8-K) | AQ |
| 2021 | Lead BET Inhibitor, VYN201, Significantly Reduces Expression of Several Key Pro-Inflamm.. | AQ |
| 2021 | Lead BET Inhibitor, VYN201, Significantly Reduces Expression of Several Key Pro-Inflamm.. | CI |
| 2021 | VYNE THERAPEUTICS : Announces Formation of Scientific Advisory Board | AQ |
| 2021 | VYNE THERAPEUTICS : Enrolls First Patient in Trial of FMX114 to Treat Atopic Dermatitis; S.. | MT |
| 2021 | VYNE THERAPEUTICS : Enrolls First Patient in Clinical Trial of FMX114 for the Treatment of.. | PU |
| 2021 | VYNE THERAPEUTICS INC. : Other Events, Financial Statements and Exhibits (form 8-K) | AQ |
| 2021 | VYNE THERAPEUTICS : Enrolls First Patient in Clinical Trial of FMX114 for the Treatment of.. | AQ |
| 2021 | VYNE Therapeutics Enrolls First Patient in Clinical Trial of FMX114 for the Treatment o.. | CI |
| 2021 | VYNE THERAPEUTICS : Partner Cutia Therapeutics Enrolls First Patient in Late-Stage Acne Dr.. | MT |
| 2021 | VYNE Therapeutics Announces its China Partner’s Enrollment of First Patient in Phase 3 .. | CI |
| 2021 | VYNE THERAPEUTICS : to Present at the Cantor Fitzgerald Investment Conference | AQ |
| 2021 | VYNE THERAPEUTICS : to Present at the H.C. Wainwright Annual Investment Conference | AQ |
| 2021 | VYNE THERAPEUTICS INC. : Change in Directors or Principal Officers (form 8-K) | AQ |
| 2021 | INSIDER TRENDS : Selling By Insiders Lingers at VYNE Therapeutics | MT |
| 2021 | INSIDER TRENDS : Insider Sales Add to 90-Day Trend at VYNE Therapeutics | MT |
| 2021 | INSIDER TRENDS : Insider 90-Day Selling Trend Prolonged at VYNE Therapeutics | MT |
| 2021 | VYNE THERAPEUTICS : Northland Adjusts VYNE Therapeutics' Price Target to $6 From $12, Keep.. | MT |
| 2021 | VYNE THERAPEUTICS : Explanatory Note (Form 8-K) | PU |
| 2021 | VYNE THERAPEUTICS INC. : Entry into a Material Definitive Agreement, Financial Statements .. | AQ |
| 2021 | VYNE THERAPEUTICS INC. : Other Events, Financial Statements and Exhibits (form 8-K) | AQ |
| 2021 | VYNE THERAPEUTICS : Management's Discussion and Analysis of Financial Condition and Result.. | AQ |
| 2021 | VYNE THERAPEUTICS : Reports Second Quarter 2021 Financial Results and Announces New Strate.. | PU |
| 2021 | VYNE THERAPEUTICS INC. : Entry into a Material Definitive Agreement, Results of Operations.. | AQ |
| 2021 | VYNE Therapeutics Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2.. | CI |
| 2021 | VYNE THERAPEUTICS : Earnings Flash (VYNE) VYNE THERAPEUTICS Posts Q2 Loss $-0.35, vs. Stre.. | MT |
| 2021 | VYNE THERAPEUTICS : Earnings Flash (VYNE) VYNE THERAPEUTICS Reports Q2 Revenue $4.3M, vs. .. | MT |
| 2021 | VYNE Therapeutics Reports Second Quarter 2021 Financial Results and Announces New Strat.. | GL |
| 2021 | VYNE THERAPEUTICS : Announces Licensing of BET Inhibitor Platform for Immuno-Inflammatory .. | AQ |
| 2021 | VYNE Therapeutics Announces Licensing of BET Inhibitor Platform for Immuno-Inflammatory.. | CI |
| 2021 | Vyne Therapeutics Initiates Process to Explore A Sale or License of Its Topical Minocyc.. | CI |
| 2021 | VYNE THERAPEUTICS INC. : Other Events (form 8-K) | AQ |
| 2021 | VYNE THERAPEUTICS : Minocycline Products Cleared for Commercial Sale in Medical Tourism Pi.. | MT |
| 2021 | VYNE THERAPEUTICS : Announces Approval of AMZEEQ® (Minocycline) and ZILXI® (Minocycline) i.. | AQ |
| 2021 | VYNE Therapeutics Inc. Announces Approval of Amzeeq (Minocycline) and Zilxi (Minocyclin.. | CI |
| 2021 | VYNE THERAPEUTICS : to Report Second Quarter 2021 Financial Results on August 12, 2021 | AQ |
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (Nederland)
Nederlands (België)
Report
